Lopinavir/ritonavir: A review of its use in the management of HIV infection

Drugs

Volumn 63, Issue 8, 2003, Pages 769-802

  Cvetkovic, Risto S ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adults; AIDS; Children; Coformulation; HIV 1; Lopinavir ritonavir; Pharmacodynamics; Pharmacokinetics; Therapeutic use

Indexed keywords

AMPRENAVIR; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CHOLESTEROL; CISAPRIDE; CYCLOSPORIN; DIHYDROERGOTAMINE; DISULFIRAM; EFAVIRENZ; ERGOMETRINE; ERGOT DERIVATIVE; ERGOTAMINE; FLECAINIDE; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; METHYLERGOMETRINE; METRONIDAZOLE; MIDAZOLAM; NELFINAVIR; PIMOZIDE; PROPAFENONE; RAPAMYCIN; RITONAVIR; TACROLIMUS; TERFENADINE; TRIAZOLAM; UNINDEXED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ASTHENIA; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONSTIPATION; COST OF ILLNESS; CUSHING SYNDROME; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG TOLERABILITY; DRY SKIN; DYSLIPIDEMIA; FEVER; FLUSHING; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LACTIC ACIDOSIS; LIPODYSTROPHY; LIPOMA; LIVER FAILURE; NAUSEA; OBESITY; PANCREATITIS; PARESTHESIA; RASH; RESPIRATION DEPRESSION; REVIEW; SALVAGE THERAPY; SIDE EFFECT; TACHYCARDIA; TACHYPNEA; TASTE DISORDER; VIRUS INFECTION; VIRUS LOAD; VOMITING;

CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; RITONAVIR;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0037251643     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363080-00004     Document Type: Review

References (150)

1. HIV/AIDS Treatment Information Service. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [online]. Available from URL: http://www.hivatis.org [Accessed 2003 Mar 7]
2. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998; 42 (12): 3218-24
3. Murphy RL, Brun S, Hicks C, et al. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001 Jan 5; 15 (1): F1-9
4. Bertz R, Lam W, Brun S, et al. Multiple-dose pharmacokinetics (PK) of ABT-378/ritonavir (ABT/r) in HIV+ subjects [abstract plus poster no. 0327]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29: San Francisco (CA), 16
5. Hurst M, Faulds D. Lopinavir. Drugs 2000 Dec; 60 (6): 1371-9
6. Debouck C. The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 1992; 8 (2): 153-64
7. De Clercq E. New developments in anti-HIV chemotherapy. Biochim Biophys Acta 2002 Jul 18; 1587 (2-3): 258-75
8. Henderson LE, Bowers MA, Sowder RC, et al. Gag proteins of the highly replicative MN strain of human immunodeficiency virus type 1: posttranslational modifications, proteolytic processing, and complete amino acid sequences. J Virol 1992 Apr; 66 (4): 1856-65
9. Kohl NE, Emini EA, Schleif WA, et al. Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988 Jul; 85: 4686-90
10. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990 Apr 20; 248: 358-61
11. Overton HA, McMillan DJ, Gridley SJ, et al. Effect of two novel inhibitors of the human immunodeficiency virus protease on the maturation of the HIV gag and gag-pol polyproteins. Virology 1990 Nov; 179: 508-11
12. Molla A, Vasavanonda S, Kumar G, et al. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 1998 Oct 25; 250: 255-62
13. Molla A, Vasavanonda S, Denissen J, et al. Effect of human serum proteins on the antiretroviral activity of ritonavir and ABT-378, potent inhibitors of HIV protease [abstract]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 22-26; Washington, DC.
14. Gustavson L, Lam W, Bertz R, et al. Assessment of the bioequivalence and food effects for liquid and soft elastic capsule coformulations of ABT-378/ritonavir (ABT-378/r) in healthy subjects [poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto
15. Abbott Laboratories. Kaletra™ (lopinavir/ritonavir) capsules and oral solution. Product label information. Abbott Laboratories. North Chicago, IL [online]. Available from URL: http://www.kaletra.com [Accessed 2002 Oct 2]
16. Boulmé R, Dugas O, Halfon P, et al. Analysis of mutational patters associated with resistance to tenofovir DF and lopinavir/ritonavir [poster no. 352]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens
17. Murphy R, Brun S, King M, et al. Lopinavir/ritonavir (Kaletra) in antiretroviral-naïve HIV+ patients: 4-year follow-up [abstract plus poster no. H-165]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27; San Diego (CA), 261
18. Bernstein B, Kempf D, King M, et al. Comparison of the emergence of resistance in a blinded phase III study with Kaletra™ (lopinavir/ritonavir) or nelfinavir plus d4T/3TC from week 24 through 96 [abstract no. 1-1768 plus poster]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago (IL), 338
19. Clumeck N, Brun S, Sylte J, et al. Kaletra (ABT-378/r) and efavirenz: one-year safety/efficacy evaluation and phenotypic breakpoints in multiple-PI-experienced patients [abstract no. 525]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4; Chicago (IL)
20. Danner S, Brun S, Richards B, et al. Kaletra (lopinavir/ritonavir) and efavirenz: 72-week safety and efficacy evaluation in multiple PI-experienced patients [poster no. 1925]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec; Chicago (IL)
21. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virologic response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir. Antiviral Ther 2002 Sep; 7 (3): 165-74
22. Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001 Aug; 75 (16): 7462-9
23. de Mendoza C, Martin-Carbonero L, Barreiro P, et al. Salvage treatment with lopinavir/ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. HIV Clin Trials 2002 Jul-Aug; 3 (4): 304-9
24. Calvez V, Cohen-Codar I, Marcelin AG, et al. Efficacy of lopinavir/ritonavir in 104 multiple PI-experienced patients according to mutational patterns: data from the French ATU program [abstract no. 234 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 154
25. Ngo Van P, Cohen-Codar I, Boer F, et al. Study of the initial response to Kaletra® in HIV treatment-experienced patients: the ATU pre-registrational cohort in France [abstract no. P236 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 155
26. Cahn P, Renz C, Saez-Llorens X, et al. Kaletra™ (ABT-378/ritonavir) in HIV-infected children at 72 weeks [poster]. 1st International AIDS Society Conference; 2001 Jul 8-11; Buenos Aires
27. Lal R, Hsu A, Granneman GR, et al. Multiple dose safety, tolerability and pharmacokinetics of ABT-378 in combination with ritonavir [abstract no. 647]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago (IL)
28. Bertz R, Foit C, Ye X, et al. Pharmacokinetics of once-daily vs twice-daily Kaletra (lopinavir/ritonavir) in HIV+ subjects [abstract no. 126]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
29. Eron J, Bernstein B, King M, et al. Once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 48-week follow-up [poster no. 409W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
30. Feinberg J, Eron J, Bernstein B, et al. Once-daily vs. twice-daily Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 72 week follow-up [abstract no. TuPeB4445]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona
31. Paukstadt W. Improved HIV therapy with protease inhibitors (lopinavir/ritonavir) [in German]. MMW Fortschr Med 2001 Apt 2; 143 Suppl. 1: 96-7
32. Kempf D, Hsu A, Issacson J, et al. Evaluation of the inhibitory quotient as a pharmacodynamic predictor of the virologic response to protease inhibitor therapy [abstract no. 7.3]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 Apt 2-4; Noordwijk
33. Boffito M, Hoggard P, Meaden RE, et al. Lopinavir/ritonavir protein binding through the 12 hour dosing interval: an in vivo evaluation [abstract plus poster no. 1407]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27; San Diego (CA)
34. Solas C, Lafeuillade A, Halfon P, et al. Discrepancies between Protease Inhibitor Concentrations and Viral Load in Reservoirs and Sanctuary Sites in Human Immunodeficiency Virus-Infected Patients. Antimicrob Agents Chemother 2003 Jan; 47 (1): 238-43
35. Min SS, Corbett AH, Rezk N, et al. Differential penetration of protease inhibitors [PI] and non-nucleoside reverse transcriptase inhibitors [NNRTI] into the female genital tract [GT] (abstract no. WePeB5966). 14th International AIDS Conference; 2002 Jul 7-12; Barcelona, 71
36. Launay O, Tod M, Louchahi K, et al. Differential diffusion of indinavir (IDV) and lopinavir (LPV) in genital secretions of HIV-infected women [abstract plus poster no. H-1712]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27; San Diego (CA)
37. Sankatsing SU, Droste J, Burger D, et al. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men [letter]. AIDS 2002 Aug 16: 16 (12): 1698-700
38. Sankatsing S, Burger D, Droste J, et al. Penetration of lopinavir into the genital tract of HIV-1-infected men [poster no. 439-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
39. Kumar GN, Jayanti V, Lee RD, et al. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: species comparison and metabolite identification. Drug Metab Dispos 1999; 27 (1): 86-91
40. Kumar GN, Rodrigues AD, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277: 423-31
41. Kumar GN, Dykstra J, Roberts EM, et al. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. Drug Metab Dispos 1999; 27 (8): 902-8
42. Kempf DJ, March KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997 Mar; 41 (3): 654-60
43. Izzedine H, Launay-Vacher V, Legrand M, et al. ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis [letter]. AIDS 2001 Mar 30; 15 (5): 662-4
44. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician 1998 Jan 1; 57 (1): 107-16
45. Rapaport S, Maroldo-Connelly L, Patterson JB, et al. Lack of methadone dose alterations or withdrawal symptoms with lopinavir/ritonavir (Kaletra™) [abstract no. TuPeB 4539]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona, 400
46. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between Kaletra™ (lopinavir/ritonavir or ABT- 378/r) and other non-HIV drugs [poster no. 438]. 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
47. Bertz R, Hsu A, Lam W, et al. Pharmacokinetic interactions between lopinavir/ritonavir (ABT-378r) and other non-HIV drugs [abstract no. P291]. AIDS 2000 Oct; 14 Suppl. 4: 100
48. Bertz R, Foit C, Chiu Y-L, et al. Multiple-dose Kaletra® (lopinavir/ritonavir) does not affect the pharmacokinetics of the CYP2D6 probe, desipramine [abstract plus poster no. 443-W]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
49. La Porte CJL, Colbers EPH, Bertz R, et al. Pharmacokinetics (PK) of two adjusted dose regimens of lopinavir/ritonavir (LPV/r) in combination with rifampin (RIF) in healthy volunteers [abstract plus poster no. A-1821]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27; San Diego (CA)
50. Jordan R, Gold L, Cummins C, et al. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ 2002 Mar 30; 324: 1-10
51. Mo H, Lu L, King M, et al. The effect of a potent, 4-drug combination (lopinavir/ritonavir, efavirenz, tenofovir DF and lamivudine) on reducing HIV unspliced mRNA and proviral DNA in PBMC [abstract plus poster no. 488-M]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
52. Bertz RJ, Foit C, Ashbrenner E, et al. Effect of amprenavir on the steady-state pharmacokinetics of lopinavir/ritonavir in HIV+ and healthy subjects [abstract plus poster no. A-1823]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27; San Diego (CA)
53. Bertz RJ, Foit C, Ashbrenner E, et al. Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects [abstract plus poster no. A-1822]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 27; San Diego (CA)
54. Bertz R, Renz C, Foit C, et al. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100mg BID) in HIV-infected subjects when taken with food [abstract no. 3.10]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 Apr 2-4; Noordwijk
55. Bertz R, Lam W, Hsu A, et al. Assessment of the pharmacokinetic interaction between ABT-378/ritonavir (ABT-378/r) and efavirenz (EFV) in healthy volunteers and in HIV+ subjects [abstract no. 424 plus poster]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 14
56. Clumeck N, Brun S, Xu Y, et al. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24-week safety/efficacy evaluation in multiple PI-experienced patients [abstract no. TuPeB3196a plus poster]. 13th International AIDS Conference; 2000 Jul 9-14; Durban
57. Lal R, Hsu A, Bertz R, et al. Evaluation of the pharmacokinetics (PK) of the concurrent administration of ABT-378/ritonavir (ABT-378/r) and nevirapine (NVP) [abstract no. 782 plus poster]. 7th Eurpoean Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon
58. Bertz R, Foit C, Burt D, et al. Assessment of the effect of nevirapine on the pharmacokinetics of lopinavir/ritonavir (Kaletra®) after multiple dosing in HIV-infected adults [abstract no. TuPeB4565 plus poster]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona, 407
59. Kearney BP, Flaherty J, Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine and lopinavir/ritonavir in healthy subjects [abstract no. P171 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 123
60. Flaherty J, Kearney B, Wolf J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir [abstract]. 1st International AIDS Society Conference; 2001 Jul 8-11; Buenos Aires, 176
61. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease: clinically important pharmacokinetic considerations. Clin Pharmacokinet 1997 Mar; 32 (3): 194-209
62. Lamotte C, Peytavin G, de Truchis P, et al. Strategies to counteract ABT378 plasma concentrations reduction resulting from the association of efavirenz (EFV) or nevirapine (NVP) in HIV-infected patients (pts) [poster no. P515]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens
63. Barry M, Wild M, Veal G, et al. Zidovudine phosphorylation in HIV-infected patients and seronegative volunteers. AIDS 1994; 8 (8): F1-5
64. Morse GD, Shelton MJ, O'Donnell AM. Comparative pharmacokinetics of antiviral nucleoside analogues. Clin Pharamacokinet 1993; 24 (2): 101-23
65. Carr RA, Andre AK, Bertz RJ, et al. Concommitant administration of ABT-378/ritonavir (ABT-378/r) results in a clinically important pharmacokinetic (PK) interaction with atorvastatin (ATO) but not pravastatin (PRA) [abstract no. 1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 334
66. Clarke S, Mulcahy F, Bergin C, et al. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 2002 Apr 15; 34 (8): 1143-5
67. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis 2002 Mar 1; 185 (5): 599-607
68. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 2002 Jun 27; 346 (26): 2039-46
69. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996 Feb 15; 334 (7): 426-31
70. Staszewski S, DeMasi R, Hill AM, et al. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998 Oct 22; 12 (15): 1991-7
71. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997 Jun 15; 126: 946-54
72. Mellors JW, Rinaldo Jr CR, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virrus in plasma. Science 1996 May 24; 272: 1167-70
73. Williams PL, Currier JS, Swindells S. Joint effects of HIV-1 RNA levels and CD4+ lymphocyte cells on the risk of specific opportunistic infections. AIDS 1999; 13 (9): 1035-44
74. Germinario A, di Luzio Paparatti U, Chevallier P, et al. Initial efficacy and safety results from the lopinavir/ritonavir (ABT-378/R) early access program in Italy [abstract no. P233 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection: 2001 Oct 28-31; Athens, 154
75. Rockstroh JK, Lohrengel B, Rode RA, et al. Efficacy and safety results from the ABT-378/R early access program in Germany [abstract no. P232 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 153
76. Montaner J, Canadian Kaletra Early Access Study Group. ABT-378/ritonavir: preliminary results of an early access program in Canada [abstract no. P230 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 152
77. Clotet B, Moreno S, Gonzalez Lahoz J, et al. Efficacy and safety results of lopinavir/R based HAART treatment in expanded access program in Spain through W24 [abstract no. 235 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 155
78. Cohen-Codar I, Boer F, Terrier R, et al. Lopinavir/ritonavir preregistration usage in France (ATU): a 2000 and 2001 insight into the therapeutic trends and outcomes in HIV treatment-experienced patients [poster no. 237]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens
79. Powderly WG, Saag MS, Chapman S, et al. Predictors of optimal virologic response to potent antiretroviral therapy. AIDS 1999 Oct 1; 13 (14): 1873-80
80. Thompson M, Brun S, King M, et al. Kaletra (lopinavir/ritonavir) in antiretroviral-naive HIV+ patients: 3-year follow-up [abstract plus poster no. 225]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 150
81. Landay A, Brun S, King M, et al. Three-year immunologic responses in antiretroviral-naive HIV+ patients treated with lopinavir/ritonavir (Kaletra) based therapy [poster no. TuPeB4439]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona
82. Perrin L, King M, Brun S, et al. Failure to achieve HIV RNA =<3 copies/ml does not predict loss of virologic response to Kaletra (lopinavir/ritonavir) therapy through 3 years [poster no. 1927]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec; Chicago (IL)
83. Johnson M, Beall G, Badley A, et al. A phase III, randomized, double-blind trial of Kaletra (ABT-378/r) + stavudine (d4T) and lamivudine (3TC) vs. nelfinavir + d4T/3TC Handout accompanying oral presentation [poster]. 5th International Congress on Drug Therapy in HIV Infection; 2000 Oct 22-26; Glasgow
84. Ruane P, Mendonca J, Timerman A, et al. Kaletra™ vs. nelfinavir in antiretroviral-naive subjects: week 60 comparison in a phase III, blinded, randomized clinical trial [abstract no. 6 plus poster]. 1st International AIDS Society Conference; 2001 Jul 8-11; Buenos Aires, 80
85. Hicks C, Brun S, King M, et al. Kaletra (lopinavir/ritonavir) therapy in single protease inhibitor experienced patients: 144-week follow-up [abstract plus poster no. 220]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 147
86. Cernohous P, Berenstein B, Mosley J, et al. Safety and efficacy of lopinavir/ritonavir in women in a phase III study of antiretroviral-naive subjects [abstract no. WePeB5972]. 14th International AIDS Conference; 2002 Jul 7-12; Barcelona, 72
87. Bernstein B, King M, Cernohous P, et al. Treatment of HIV+ subjects co-infected with hepatitis B or C: week 60 safety and efficacy comparison of lopinavir/ritonavir vs. nelfinavir from a phase III blinded randomized clinical trial [abstract no. P228 plus poster]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens, 151
88. Becker S, Brun S, Bertz R, et al. ABT-378/ritonavir (ABT-378/r) and efavirenz: 24 week safety/efficacy evaluation in multiple PI experienced patients [abstract no. 697]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20: Toronto, 294
89. Castro KG, Ward JW, Slutsker L, et al. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992 Dec 18; 41 (RR-17): 1-18
90. Calvez V, Cohen Codar I, Marcelin AG, et al. Analysis of the correlation between baseline genotypic profile and virological response to lopinavir/ritonavir in 104 multiple protease inhibitor-experienced patients treated under the lopinavir/ritonavir Authorisation Temporaire d'Utilisation program [abstract no. 90 plus poster]. Antiviral Ther 2001; 6 Suppl. 1: 69-70
91. Bernstein B, Moseley J, King M, et al. Safety of Kaletra™: data from phase 11 and phase III clinical trials [poster]. 1st International AIDS Society Conference; 2001 Jul 8-11: Buenos Aires
92. Boer F, Cohen-Codard I, Terrier R, et al. Collection of drug adverse events in pre-registrational access programs: what relevance compared to controlled studies? Analysis of the Franch ATU cohort for Kaletra® [poster no. 238]. 8th European Conference on Clinical Aspects and Treatment of HIV-Infection; 2001 Oct 28-31; Athens
93. Kikuchi Y, Genka I, Ishizaki A, et al. Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2002 Aug 15; 35 (4): 488-90
94. Luo MP, Boggs B, Bernstein B, et al. Cost-consequence comparison of lopinavir/ritonavir (LPV/r) vs. nelfinavir (NFV) therapy in treating antiretroviral naive patients using clinical trial data [abstract no. PIN14]. Value Health Nov-Dec 2002; 5 (6): 566-7
95. Simpson KN, Voit EO, Goodman R, et al. Economic comparison of lopinavir/r versus nelfinavir in combination with 3Tc and d4T in ARV-naive patients [abstract no. P301]. AIDS 2000 Oct; 14 Suppl. 4: 103
96. Simpson KN, Chumney E, Luo MP, et al. Five-year budget impact and lifetime cost effectiveness of a lopinavir/ritonavir (LPV/r) vs. a nelfinavir (NFV) containing regimen for treatment-naive patients [abstract plus poster no. PIN13]. Value Health Nov-Dec 2002; 5 (6): 566
97. Abbott Laboratories. Abbott Laboratories' Kaletra® (lopinavir/ritonavir) attains status as most-prescribed protease inhibitor for the treatment of HIV [online]. Available from URL: http://abbott.com [Accessed 2002 Nov II]
98. Worldwide HIV & AIDS epidemic statistics [online]. Available from URL: http://www.avert.org/worldstatinfo.htm [Accessed 2002 Nov 18]
99. U.S. Food and Drug Administration. Approved drugs for HIV/AIDS and AIDS-related conditions [online]. Available from URL: http://www.fda.gov/oashi/aids/stat_app.html [Accessed 2002 Dec 4]
100. Davies E, Morlese JF, Bower M, et al. Drug treatment of HIV and AIDS. Hospital Pharmacist 2001 Apr; 8 (4): 96-104
101. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 2001; 15 (11): 1369-77
102. Moyle G. Use of HIV protease inhibitors as pharmacoenhancers. The AIDS Reader 2001; 11 (2): 87-98
103. Moyle GJ, Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med 2001 Apr; 2 (2): 105-13
104. van Heeswijk RPG, Veldkamp AI, Mulder JW, et al. Combination of protease inhibitors for the treatment of HIV-I-infected patients: a review of pharmacokinetics and clinical experience. Antivir Ther 2001 Dec; 6 (4): 201-29
105. Dragsted UB, Gerstoft J, Youle M. The interim analysis of a phase IV, randomised, open-label, multi-centre trial to evaluate safety and efficacy of lopinavir (400/100mg bid) versus saquinavir/ritonavir (1000/100mg bid) in adult HIV-1 infection: The MaxCmin trial [poster no. PL-14.5]. 6th International Congress on Drug Therapy in HIV Infection; 2002 Nov 17-21; Glasgow
106. Centers for Disease Control and Prevention. HIV/ADIS Surveillance Report 2001. HIV/AIDS Surveillance Report 2002 Sep 25; 13 (2): 1-44
107. Joint United Nations Programme on HIV/AIDS. Fact sheet: high-income countries [online]. Available from URL: httm://www.unaids.org/barcelona/presskit/factsheets/FShighincome_en.htm [Accessed 2002 Nov 18]
108. Adler MW. Development of the epidemic. Clinical review: ABC of AIDS. BMJ 2001 May 19; 322 (7296): 1226-9
109. Altice FL, Fried/and GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 1999; 13 (8): 957-62
110. Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 1999; 19 (4): 471-2
111. Clarke S, Mulcahy F, Back D, et al. Managing methadone and non-nucleoside reverse transcriptase inhibitors: guidelines for clinical practice [abstract no. 88]. 7th Conference on Retroviruses and Opportunistic Infections; 2002 Jan 30-Feb 2; San Francisco (CA)
112. Kashuba ADM, Dyer JR, Kramer LM, et al. Antiretoviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999 Aug; 43 (8): 1817-26
113. Vernazza PL, Troiani L, Flepp MJ, et al. Potent antiretroviral treatment of HIV-infection results in suppression of the seminal shedding of HIV. AIDS 2000; 14 (2): 117-21
114. van Praag RME, Weverling GJ, Portegies P, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14 (9): 1187-94
115. Eron JJ, Vernazza PL, Johnston DM, et al. Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS 1998; 12 (15): F181-9
116. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998 Jul 1; 280 (1): 67-71]
117. Günthard HF, Havlir DV, Fiscus S, et al. residual human immunodeficiency virus (HIV) type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. J Infect Dis 2001 May 1; 183: 1318-27
118. Eron JJ, Smeaton LM, Fiscus SA, et al. The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS Clinical Trials Group Protocol 850). J Infect Dis 2000 May; 181: 1622-8
119. Taylor S, Back DJ, Workman J, et al. Poor penetration of the male genital tract by HIV-1 protease inhibitors. AIDS 1999; 13 (7): 859-60
120. Henry K, Chinnock BJ, Quinn RP, et al. Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988 May 27; 259 (20): 3023-6
121. Pereira AS, Kashuba ADM, Fiscus SA, et al. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden. J Infect Dis 1999 Dec; 180: 2039-43
122. Taylor S, van Heeswijk RPG, Hoetelmans RMW, et al. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men. AIDS 2000; 14 (13): 1979-84
123. van Praag RME, van Heeswijk RPG, Jurriaans S, et al. Penetration of the nucleoside analogue abacavir into the genital tract of men infected with human immunodeficiency virus type 1. Clin Infect Dis 2001 Sep 20; 33 (8): e91-2
124. Taylor S, Reynolds H, Sabin CA, et al. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men. AIDS 2001; 15 (15): 2051-3
125. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and rpevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract no. LB6a]. 3rd Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28-Feb 1; Washington, DC, 162
126. Merck & Co. Inc. Crixivan® (indinavir sulfate) capsules. Product label information. Merck & Co., Inc., Whitehouse Station, NJ [online]. Available from URL: http://www.merck.com/product/usa/crixivan/cns/default.jsp [Accessed 2002 Nov 20]
127. Abbott Laboratories. Norvir® (ritonavir capsules [Soft Gelatin] and oral solution). Product label information. Abbott Laboratories. North Chicago, IL [online]. Available from URL: httm://www.norvir.com [Accessed 2002 Nov 20]
128. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995 Dec 7; 333 (23): 1534-40
129. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998 May 7; 12 (7): F51-8
130. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 Jun 19; 353 (9170): 2093-9
131. Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000; 30 Suppl. 2: S135-42
132. Walli R, Herfort O, Minchl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998 Dec; 12 (15): F167-73
133. Moyle GJ, Gazzard BG. A risk-benefit assessment of HIV protease inhibitors. Drug Saf 1999 Apr; 20 (4): 299-321
134. Segerer S, Bogner JR, Walli R, et al. Hyperlipidemia under treatment with proteinase inhibitors. Infection Mar-Apr 1999; 27: 77-81
135. Panse I, Vasseur E, Raffin-Sanson ML, et al. Lipodystrophy associated with protease inhibitors. Br J Dermatol 2000 Mar; 142 (3): 496-500
136. Jutte A, Schwenk A, Franzer C, et al. Increasing morbidity from myocardial infarction during HIV protease inhibitor treatment? [letter]. AIDS 1999 Sep 10; 13 (13): 1796-7
137. Currier JS, Boyd F, Kawabata H, et al. Diabetes mellitus in HIV-infected individuals [abstract plus poster no. 677-T]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle (WA)
138. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999 Dec 24; 13 (18): 2493-505
139. Anis AH, Guh D, Hogg RS, et al. The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 2000 Oct; 18 (4): 393-404
140. Sendi P, Palmer AJ, Gafni A, et al. Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics 2001; 19 (7): 709-13
141. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001 Mar 15; 344 (11): 824-31
142. GlaxoSmithKline. Agenerase® (amprenavir) Capsules. Prescribing infomation. GlaxoSmithKline. Research Triangle Park, NC [online]. Available from URL: http://www.agenerase.com [Accessed 2002 Nov 22]
143. Agouron Pharmaceuticals Inc. Viracept® (nelfinavir mesylate) Tablets and Oral Powder. Prescribing information. Agouron Pharmaceuticals, Inc. La Jolla, CA [online]. Available from URL: http://www.viracept.com [Accessed 2002 Nov 22]
144. Roche Pharmaceuticals. Fortovase® (saquinavir) soft gelatin capsules. Prescribing information. Roche Laboratories Inc. Nutley, NJ [online]. Available from URL: httm://www.fortovase.com [Accessed 2002 Nov 22]
145. van Heeswijk R, Cardiello P, Monhaphol T, et al. Once-daily dosing of 1,600 mg saquinavir (soft-gelatin capsules; SQV-SGC) plus low dose ritonavir (RTV, 100 mg) in HIV-1-infected Thai patients: pharmacokinetics (PK) and clinical experience (HIV-NAT 001.3) [abstract]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 Apr 2-4; Noordwijk
146. Saag MS, Kilby M, Ehrensing E, et al. Modulation of saquinavir steady-state pharmacokinetics with 'baby' doses of ritonavir in healthy volunteers [abstract no. 829]. 7th Eurpoean Conference on Clinical Aspects and Treatment of HIV-Infection; 1999 Oct 23-27; Lisbon
147. Anne-Marie T, Paci-Bonaventure S, Goujard C, et al. Therapeutic drug monitoring of amprenavir combined with ritonavir as salvage therapy in HIV-1 infected patients [abstract no. TuPeB3305]. 13th International AIDS Conference; 2000 Jul 9-14; Durban, 380
148. van Heeswijk RPG, Veldkamp Al, Hoetelmans RMW, et al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritoanvir in twice daily dosing regimens in HIV-1-infected individuals. AIDS 1999 Oct 1; 13 (14): F95-9
149. O'Brien WA, Atkinson TA, Han X, et al. Combination therapy with indinavir and ritonavir in antiretroviral-experienced patients [abstract no. 2209]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), 539
150. Casado JL, Moreno A, Marti-Belda P, et al. Increased indinavir levels using twice daily ritonavir/indinavir ar 100/800mg improves virological response even after multiple failure [abstract no. 1170]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto, 301